文献速递复苏、休克与脓毒症儿科与产科急症

儿童院外心脏骤停中肾上腺素使用及首次给药时间与结局的评估

Evaluation of Use of Epinephrine and Time to First Dose and Outcomes in Pediatric Patients With Out-of-Hospital Cardiac Arrest.
PubMed 文献 · JAMA Netw Open · 2023-03-01
一句话结论儿童院外心脏骤停中,院前使用肾上腺素与出院存活率升高相关(RR 2.09),但给药时间与存活无关(交互P=0.34)。

该队列研究基于美国与加拿大10个站点的复苏结局联盟流行病学登记,纳入2011年4月至2015年6月由急救医疗服务治疗的1032例18岁以下院外心脏骤停患者。765例(74.1%)接受了肾上腺素,267例(25.9%)未接受;高级生命支持(ALS)人员到达至首次给药的中位时间为9(IQR 6.2-12.1)分钟。采用时间依赖倾向评分匹配后(1432例),肾上腺素组出院存活率高于风险组(6.3% vs 4.1%;风险比2.09;95%CI 1.29-3.40),但给药时间与出院存活无关(交互P=0.34)。

要点

  • 儿童院外心脏骤停患者中,院前接受肾上腺素者出院存活率高于未接受者(6.3% vs 4.1%;RR 2.09;95%CI 1.29-3.40)。
  • ALS人员到达至首次给予肾上腺素的中位时间为9(IQR 6.2-12.1)分钟。
  • 肾上腺素给药时间与出院存活无关(交互P=0.34)。
  • 匹配队列共1432例(肾上腺素组716例,风险组716例)。

适用人群与场景

  • 年龄<18岁的儿童院外心脏骤停患者,由急救医疗服务治疗,数据来自美国与加拿大10个站点的复苏结局联盟流行病学登记(2011年4月至2015年6月)。

处置流程与药物剂量

  • 院前给予肾上腺素(静脉或骨内途径),具体剂量与频次原文未报告;ALS人员到达至首次给药的中位时间为9(IQR 6.2-12.1)分钟。

研究设计与关键结果

  • 研究类型为队列研究,纳入1032例合格患者(中位[IQR]年龄1[0-10]岁),625例(60.6%)为男性;765例(74.1%)接受肾上腺素,267例(25.9%)未接受。
  • 采用时间依赖倾向评分匹配后(匹配队列1432例),肾上腺素组出院存活45/716(6.3%),风险组29/716(4.1%);风险比2.09;95%CI 1.29-3.40。
  • 肾上腺素给药时间与出院存活无关(给药与匹配时间交互P=0.34)。

证据类型、等级与局限

  • 证据类型:队列研究;局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在美国与加拿大的儿童院外心脏骤停患者中,给予肾上腺素与出院存活相关,而给药时间与存活无关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: While epinephrine has been widely used in prehospital resuscitation for pediatric patients with out-of-hospital cardiac arrest (OHCA), the benefit and optimal timing of epinephrine administration have not been fully investigated.

OBJECTIVES: To evaluate the association between epinephrine administration and patient outcomes and to ascertain whether the timing of epinephrine administration was associated with patient outcomes after pediatric OHCA.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study included pediatric patients (<18 years) with OHCA treated by emergency medical services (EMS) from April 2011 to June 2015. Eligible patients were identified from the Resuscitation Outcomes Consortium Epidemiologic Registry, a prospective OHCA registry at 10 sites in the US and Canada. Data analysis was performed from May 2021 to January 2023.

EXPOSURES: The main exposures were prehospital intravenous or intraosseous epinephrine administration and the interval between arrival of an advanced life support (ALS)-capable EMS clinician (ALS arrival) and the first administration of epinephrine.

MAIN OUTCOMES AND MEASURES: The primary outcome was survival to hospital discharge. Patients who received epinephrine at any given minute after ALS arrival were matched with patients who were at risk of receiving epinephrine within the same minute using time-dependent propensity scores calculated from patient demographics, arrest characteristics, and EMS interventions.

RESULTS: Of 1032 eligible individuals (median [IQR] age, 1 [0-10] years), 625 (60.6%) were male. 765 patients (74.1%) received epinephrine and 267 (25.9%) did not. The median (IQR) time interval between ALS arrival and epinephrine administration was 9 (6.2-12.1) minutes. In the propensity score-matched cohort (1432 patients), survival to hospital discharge was higher in the epinephrine group compared with the at-risk group (epinephrine: 45 of 716 [6.3%] vs at-risk: 29 of 716 [4.1%]; risk ratio, 2.09; 95% CI, 1.29-3.40). The timing of epinephrine administration was also not associated with survival to hospital discharge after ALS arrival (P for the interaction between epinephrine administration and time to matching = .34).

CONCLUSIONS AND RELEVANCE: In this study of pediatric patients with OHCA in the US and Canada, epinephrine administration was associated with survival to hospital discharge, while timing of the administration was not associated with survival.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Amoako J, Komukai S, Izawa J, et al. Evaluation of Use of Epinephrine and Time to First Dose and Outcomes in Pediatric Patients With Out-of-Hospital Cardiac Arrest. JAMA Netw Open. 2023. PMID: 36976555. doi:10.1001/jamanetworkopen.2023.5187

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。